Mozobil is approved by the FDA to be used in combination with another
agent filgrastim to
mobilize hematopoietic
stem cells
to the peripheral blood
for
collection
and subsequent autologous
transplantation
in patients living with
non-Hodgkin’s lymphoma (NHL) or multiple
myeloma (MM).
Our passion is to facilitate access and provide support to patients. Explore available resources, including the Sanofi Patient Connection Support Program.